Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study
Riancho, Javier, Setien, Sonia, Sánchez de la Torre, Jose Ramón, Torres-Barquin, Marta, Misiego, Mercedes, Pérez, José Luis, Castillo-Triviño, Tamara, Menéndez-García, Cristina, Delgado-Alvarado, Manuel
Published in Frontiers in immunology (25.03.2021)
Published in Frontiers in immunology (25.03.2021)
Get full text
Journal Article
Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
Santiago-Setien, Pilar, Barquín-Rego, Cristina, Hernández-Martínez, Paula, Ezquerra-Marigomez, María, Torres-Barquin, Marta, Menéndez-Garcia, Cristina, Uriarte, Fernando, Jiménez-López, Yésica, Misiego, Mercedes, Sánchez de la Torre, Jose Ramón, Setien, Sonia, Delgado-Alvarado, Manuel, Riancho, Javier
Published in Frontiers in immunology (01.02.2023)
Published in Frontiers in immunology (01.02.2023)
Get full text
Journal Article